Method of Addition of Bromocriptine to the Drug Regime of Patients with Advanced Parkinson’s Disease
- 1 February 1981
- journal article
- research article
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences
- Vol. 8 (1) , 31-34
- https://doi.org/10.1017/s0317167100042803
Abstract
Using a method of a gradual increase of bromocriptine with a concomitant reduction of Sinemet® (levodopa 250 mg + carhidopa 25 mg), 19 patients with advanced Parkinson’s disease have been treated for periods of up to 22 months and 16 of them have shown improvements of varying degrees. Eighteen patients were able to tolerate bromocriptine addition, with early transient adverse effects occurring in seven cases. In contrast to several previously reported studies, it was found necessary to withdraw bromocriptine in only one case.With the drugs currently available, bromocriptine has a role in the management of patients with advanced Parkinson’s disease. The method described here may allow a greater number of patients to be given a trial with this drug.This publication has 6 references indexed in Scilit:
- The role of bromocriptine in the treatment of parkinsonismNeurology, 1979
- Bromocriptine in Parkinson diseaseNeurology, 1979
- Long-term treatment of Parkinson's disease with bromocriptine.Journal of Neurology, Neurosurgery & Psychiatry, 1979
- Bromocriptine in Parkinsonism.BMJ, 1978
- LONG-TERM TREATMENT OF PARKINSONISM WITH BROMOCRIPTINEThe Lancet, 1978
- IDIOPATHIC PARKINSONISM TREATED WITH BROMOCREPTINEThe Lancet, 1975